Abstract Objective To summarize the results of stereotactic radiation therapy (SRT) with or without whole-brain radiotherapy (WBRT) in the treatment of multiple brain metastasis. Methods From May 1995 to April 2010, totally 98 newly diagnosed multiple (2－13 lesions) brain metastases patients were treated in our centre. Forty-four patients were treated with SRT alone and 54 with SRT+WBRT. Dose fractionation schemes were 15－26 Gy in 1 fraction or 24.0－52.5 Gy in 2－15 fractions with 3.5－12.0 Gy per fraction,depending on the tumor volume, location, and history of prior irradiation. Kaplan-Meier and Cox proportional hazards regression analyses were used for survival analysis. The median age of the whole group was 55 years. The survival time was calculated from the date of radiation treatment to the day of death by any cause. Results The median follow-up time for the whole group was 12 months, and the follow-up rate was 100%.The median overall survival time was 13.5 months for the whole group, there was no difference between SRT alone group and SRT+WBRT group (13.0 months vs.13.5 months, χ2=0.31,P=0.578). The Karnofsky Performance Score (KPS) at the time of treatment (χ2=6.25,P=0.012), the interval between the diagnosis of the primary tumor and brain metastases (χ2=7.34,P=0.025) and the status of extracranial metastases (χ2=4.20,P=0.040) were independent prognosis factors for survival in multivariate analyses. Conclusions Stereotactic radiation therapy is an effective and alternative treatment choice for multiple brain metastases.
CHEN Xiu-jun,XIAO Jian-ping,LI Xiang-pan et al. The role of stereotactic radiation therapy and whole-brain radiotherapy in the treatment of multiple brain metastases[J]. Chinese Journal of Radiation Oncology, 2012, 21(1): 1-4.
CHEN Xiu-jun,XIAO Jian-ping,LI Xiang-pan et al. The role of stereotactic radiation therapy and whole-brain radiotherapy in the treatment of multiple brain metastases[J]. Chinese Journal of Radiation Oncology, 2012, 21(1): 1-4.
[1] Posner JB, Management of brain metastases. Rev Neurol,1992,148:477-487. [2] Nussbaum ES, Djalilian HR, Cho KH, et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer,1996,78:1781-1788. [3] Delattre JY, Krol G, Thaler HT, et al. Distribution of brain metastases. Arch Neurol,1988,45:741-744. [4] Komarnicky LT, Phillips TL, Martz K, et al. A randomized phase Ⅲ protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG 79-16). Int J Radiat Oncol Biol Phys,1991,20:53-58. [5] Sause WT, Scott C, Kirsch R, et al. Phase Ⅰ/Ⅱ trial of accelerated fractionation in brainmetastases, RTOG 85-28. Int J Radiat Oncol Biol Phys,1993,26:653-657. [6] Phillips TL, Scott CB, Leibel S, et al. Results of a randomized comparison of radiotherapy and bromodeoxyuridine to radiotherapy alone for brain metastases:report of RTOG trial89-05. Int J Radiat Oncol Biol Phys,1995,33:339-348. [7] Murray KJ, Scott C, Greenberg HM, et al. A randomized phase Ⅲ study of accelerated hyperfractionation versus standard in patients with unresected brain metastasis:a report of RTOG9104. Int J Radiat Oncol Biol Phys,1997,39:571-574. [8] David WA, Charles BS, Paul WS, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases:phase Ⅲ results of the RTOG 9508 randomised trial. Lancet,2004,363:1665-1672. [9] James LF, Sachin B, Sumit K, et al. Stereotactic radiosurgery in the management of brain metastases:an institutional retrospective analysis of survival. Int J Radiat Oncol Biol Phys,2010,76:1486-1492. [10] Ajay KB, John CK, Douglas K, et al. Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys,2006,64:898-903. [11] Kim SH, Weil RJ, Chao ST, et al. Stereotactic radiosurgical treatment of brain metastases in older patients. Cancer,2008,113:834-840. [12] Flannery TW, Suntharalingam M, Regine WF, et al. Long-term survival in patients with synchronous, solitary brain metastasis from non-small cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys,2008,72:19-23. [13] Sanghavi SN, Miranpuri SS, Chappell R, et al. Radiosurgery for patients with brain metastases:a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys,2001,51:426-434. [14] Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of prognostic factors in patients with brain metastases:a review of 1292 patients. Int J Radiat Oncol Biol Phys,1999,43:795-803. [15] Lorenzoni J, Devriendt D, Massager N, et al. Radiosurgery for treatment of brain metastases:estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys,2004,60:218-224. [16] Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases:a randomized controlled trial. JAMA,2006,295:2483-2491. [17] Rades D, Dziggel L, Haatanen T, et al. Scoring system to estimate intracranial control and survival rates of patients irradiated for brain metastases. Int J Radiat Oncol Biol Phys,2011,In press. [18] Kim EY, Maciunas RJ, Williams JM, et al.153 Tumor volume is a predictor of overall survival for patients with brain metastases who undergo gamma knife stereotactic radiosurgery. Int J Radiat Oncol Biol Phys,2006,66(3 Suppl):86. [19] Bhatnagar AK, Flickinger JC, Kondziolka D, et al. Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys,2006,64:898-903. [20] Jawahar A, Shaya M, Campbell P, et al. Role of stereotactic radiosurgery as a primary treatment option in the management ofnewly diagnosed multiple (3－6) intracranial metastases. Surg Neurol,2005,64:207-212. [21] Sheehan J, Kondziolka D, Flickinger J, et al. Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain:outcomes and prognostic factors. J Neurosurg,2005,102 Suppl:247-254. [22] Selek U, Chang EL, Hassenbusch SJ, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys,2004,59:1097-1106. [23] Edward S, Charles S, Luis S, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain Metastases:final report of RTOG protocol 90-05.Int J Radiat Oncol Biol Phys,2000,47:291-298. [24] Kim YJ, Cho KH, Kim JY, et al. Single-dose versus fractionated
stereotactic radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys,2011,In press. [25] Shehata MK, Young B, Reid B, et al. Stereotactic radiosurgery of 468 brain metastases< or=2 cm:implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys,2004,59:87-93. [26] Chidel MA, Suh JH, Reddy CA, et al. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys,2000,47:993-999. [27] Aoyama H, Tago M, Katoh N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys,2007,68:1388-1395. [28] Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation:a randomised controlled trial. Lancet Oncol,2009,10:1037-1044.
2012, Vol. 21 
